Premium
Circulating ctDNA methylation quantification of two DNA methyl transferases in papillary thyroid carcinoma
Author(s) -
Khatami Fatemeh,
TeimooriToolabi Ladan,
Heshmat Ramin,
Nasiri Shirzad,
Saffar Hiva,
Mohammadamoli Mahsa,
Aghdam Mohammad Haddadi,
Larijani Bagher,
Tavangar Seyed Mohammad
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.29007
Subject(s) - methylation , methyltransferase , dna methylation , dna methyltransferase , thyroid cancer , o 6 methylguanine dna methyltransferase , microbiology and biotechnology , cancer research , goiter , thyroid carcinoma , chemistry , biology , cancer , dna , gene , thyroid , gene expression , genetics
Papillary thyroid cancer (PTC) is the most common type of cancer among thyroid malignancies. Tumor‐related methylation of circulating tumor DNA (ctDNA) in plasma could represent tumor specific alterations can be considered as good biomarkers in circulating tumor cells. In this study, we studied the methylation status of seven promoter regions of two DNA methyl Transferases (MGMT and DNMT1) genes as the methylated ctDNA in plasma and tissue samples of patients with PTC and goiter patients as noncancerous controls. Methods: Both ctDNA and tissue genomic DNA of 57 PTC and 45 Goiter samples were isolated. After bisulfite modification, the methylation status was studied by Methylation‐Sensitive High Resolution Melting (MS‐HRM) assay technique. Four promoter regions of O6‐methylguanine‐DNA methyltransferase (MGMT) and three promoter regions of DNA methyltransferase 1 (DNMT1) were assessed. Results: From seven candidate promoter regions of two methyltrasferase coding genes, the methylation status of ctDNA within MGMT (a), MGMT (c), MGMT (d), and DNMT1 (b) were meaningfully different between PTC cases and controls. However, the most significant differences were seen in circulating ctDNA MGMT (c) which was hypermethylated in 25 (43.9 %) of patients with PTC vs 2 (4. 4 %) of goiter samples. Between two selected DNA methyl transferase, the methylation of MGMT as the maintenance methyltransferase was significantly higher in PTC cases than goiter controls ( P ‐value < .001). The resulting areas under the receiver operating characteristic (ROC) curve were 0.78 for MGMT (d) for PTC versus goiter samples that can represent the overall ability of MGMT (d) methylation status to discriminate between PTC and goiter patients. Conclusion: Among seven candidate regions of ctDNA the MGMT (c) and MGMT (d) showed higher sensitivity and specificity for PTC as a suitable candidates as biomarkers of PTC.